Exact Sciences
Market Cap
US$11.6b
Last Updated
2020/09/20 06:00 UTC
Data Sources
Company Financials +
Executive Summary
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Slightly overvalued with limited growth.
Similar Companies
Share Price & News
How has Exact Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.7%
EXAS
6.7%
US Biotechs
0.09%
US Market
1 Year Return
-25.5%
EXAS
31.2%
US Biotechs
12.6%
US Market
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 31.2% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 12.6% over the past year.
Shareholder returns
| EXAS | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.7% | 6.7% | 0.09% |
| 30 Day | -3.4% | 1.4% | -1.6% |
| 90 Day | -12.2% | -1.2% | 7.9% |
| 1 Year | -25.5%-25.5% | 33.4%31.2% | 15.2%12.6% |
| 3 Year | 68.6%68.6% | 17.9%12.2% | 38.9%29.6% |
| 5 Year | 309.9%309.9% | 19.6%11.4% | 87.6%66.5% |
Price Volatility Vs. Market
How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt1 month ago | Simply Wall St
Can You Imagine How Jubilant Exact Sciences' (NASDAQ:EXAS) Shareholders Feel About Its 296% Share Price Gain?3 months ago | Simply Wall St
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of DebtValuation
Is Exact Sciences undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EXAS ($77.47) is trading below our estimate of fair value ($185.93)
Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EXAS is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
66.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXAS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXAS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXAS's revenue (21.9% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: EXAS's revenue (21.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAS is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Exact Sciences performed over the past 5 years?
0.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXAS is currently unprofitable.
Growing Profit Margin: EXAS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EXAS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.
Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: EXAS has a negative Return on Equity (-6.15%), as it is currently unprofitable.
Next Steps
Financial Health
How is Exact Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.5B) exceed its short term liabilities ($222.3M).
Long Term Liabilities: EXAS's short term assets ($1.5B) do not cover its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: EXAS's debt to equity ratio (62.1%) is considered high.
Reducing Debt: EXAS's debt to equity ratio has increased from 0.9% to 62.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EXAS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EXAS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Exact Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Kevin Conroy (54 yo)
11.42yrs
Tenure
US$18,716,543
Compensation
Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy serves as Director at ARYA Sciences Acquisition Corp since 2018. Mr. Conroy has been the Chief Ex ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD18.72M) is above average for companies of similar size in the US market ($USD11.35M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 11.42yrs | US$18.72m | 0.69% $ 80.6m | |
| Chief Financial Officer | 3.83yrs | US$5.12m | 0.026% $ 3.1m | |
| Senior Vice President of Operations | 5.67yrs | US$3.95m | 0.14% $ 16.2m | |
| Chief Administrative Officer | 2.17yrs | US$5.07m | 0.036% $ 4.2m | |
| Senior Vice President of Pipeline | 1.58yrs | US$4.06m | 0.0018% $ 208.2k | |
| General Manager of Precision Oncology | no data | US$2.10m | 0.0068% $ 789.9k | |
| Chief Information Officer | 5.67yrs | no data | no data | |
| Chief Science Officer and Senior VP of Research & Development | 1.67yrs | no data | 0.0083% $ 969.1k | |
| Associate Manager of Investor Relations | no data | no data | no data | |
| Chief Compliance Counsel & VP | 5.67yrs | no data | no data | |
| Head of Sales | 1.75yrs | no data | no data | |
| Vice President of Marketing | 1.75yrs | no data | no data |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Management: EXAS's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 11.42yrs | US$18.72m | 0.69% $ 80.6m | |
| Director | 1.17yrs | US$780.00k | 0.0063% $ 731.7k | |
| Independent Director | 10.17yrs | US$329.02k | 0.010% $ 1.2m | |
| Independent Director | 5.58yrs | US$331.02k | 0.0076% $ 888.8k | |
| Independent Director | 11.42yrs | US$326.02k | 0.053% $ 6.1m | |
| Independent Director | 2.83yrs | US$325.02k | 0.0062% $ 717.8k | |
| Independent Director | 0.42yr | no data | 0.0056% $ 656.1k | |
| Independent Director | 1.5yrs | US$811.49k | 0.0072% $ 833.0k | |
| Independent Director | 7.42yrs | US$319.02k | 0.015% $ 1.7m | |
| Director | 0.17yr | no data | 0.0042% $ 492.1k | |
| Lead Independent Director | no data | US$347.52k | 0.022% $ 2.5m | |
| Independent Director | 1.17yrs | US$694.00k | 0.0058% $ 677.1k |
2.8yrs
Average Tenure
65yo
Average Age
Experienced Board: EXAS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.
Top Shareholders
Company Information
Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Exact Sciences Corporation
- Ticker: EXAS
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$11.633b
- Shares outstanding: 150.17m
- Website: https://www.exactsciences.com
Number of Employees
Location
- Exact Sciences Corporation
- 441 Charmany Drive
- Madison
- Wisconsin
- 53719
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EXAS | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2001 |
| EXK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2001 |
Biography
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to de ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/20 06:00 |
| End of Day Share Price | 2020/09/18 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.